Fibromyalgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Fibromyalgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Fibromyalgia, also called fibromyalgia syndrome, is a chronic neurologic disorder, which causes severe pain all over the body. The cause of fibromyalgia is unknown, however, it can be caused due to various factors, including genetics cause, physical or emotional trauma or due to infections. The symptoms related to fibromyalgia includes widespread pain, severe fatigue, sleep problems, cognitive difficulties, and others. Various medications such as antidepressant drugs, antiepileptic drugs, muscle relaxants, and analgesics are used for the management and treatment of fibromyalgia.
Market Dynamics
Key players in the market are focusing on frequent research and development activities for development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period. For instance, drug candidate IMC-1 is being developed by Innovative Med Concepts, which received fast track designation from the U.S. FDA in 2016
In December 2018, Aptinyx Inc. announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.
In 2021, Innovative Med Concepts announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.
Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. have launched generic drugs for fibromyalgia treatment in the market.
Launch of generic versions of branded fibromyalgia drugs is expected to affect the revenue of branded drugs. However, it is expected to increase adoption and affordability of drugs and support fibromyalgia treatment market growth in the near future.
For instance, in December 2013, Sun Pharmaceutical Industries Ltd. announced that the U.S. FDA granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg, and 60 mg.
Key features of the study:
This report provides in-depth analysis of fibromyalgia treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global fibromyalgia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the fibromyalgia treatment market
Detailed Segmentation:
Global Fibromyalgia Treatment Market, By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
Global Fibromyalgia Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Fibromyalgia Treatment Market, By Region:
North America
By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class :
Antidepressants
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
Analgesics
Others (Including Pipeline Drugs)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Eli Lilly and Company*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Pfizer, Inc.
Novartis AG
Allergan plc.
Sun Pharmaceutical Industries Ltd.
Aptinyx, Inc.
Prismic Pharmaceuticals, Inc.
Innovative Med Concepts, Inc.
Intec Pharma Ltd.
Astellas Pharma Inc.
“*” marked represents similar segmentation in other categories in the respective section.